^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Immunosuppressant

    Related drugs:
    1m
    Age-Stratified Conditioning Regimen Efficacy for MDS Haplo-HSCT (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    cytarabine • cyclophosphamide • fludarabine IV • busulfan
    1m
    Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma. (PubMed, Front Immunol)
    She was successfully treated with high-dose glucocorticoids, mycophenolate mofetil, and intravenous immunoglobulin with resolution of presenting symptoms...Additionally, we identified a differentiated CD27- CD28- effector memory (EM) CD4+ subset that was associated with clinical disease activity and contracted with glucocorticoid use administration. This illustrates a unique case of a patient who was successfully treated for IM3OS and highlights the potential use of flow cytometry to provide insight into the underlying pathophysiology of irAEs, and to guide and gauge response to immunomodulatory therapy, thus facilitating a precision medicine approach within the diagnostic and treatment framework for irAEs.
    Journal • Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD27 (CD27 Molecule)
    1m
    ATG Exposure in T Replete Transplant for Hematological Malignancies: Real World Analysis from BMT CTN 1202. (PubMed, Res Sq)
    Traditional weight-based dosing results in variable rabbit anti-thymocyte globulin (rATG) clearance, delaying CD4 + Tcell-immune-reconstitution (CD4 + IR) and impacting outcomes...Low post-HCT rATG-exposure (< 30AUxd/mL) but not absent correlated with higher OS, lower relapse, and lower GVHD related deaths. Model-based-dosing could be used to target optimal post-HCT rATG-exposure and improve HCT outcomes.
    Journal • Real-world evidence
    |
    CD4 (CD4 Molecule)
    2ms
    MT2015-29: Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (clinicaltrials.gov)
    P2, N=300, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
    |
    NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide
    2ms
    Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Fox Chase Cancer Center
    New P2 trial • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    prednisone
    2ms
    Paraneoplastic Myeloperoxidase (MPO)-Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Revealing Colon Adenocarcinoma in a Patient With Controlled HIV Infection: A Case Report. (PubMed, Cureus)
    Treatment included glucocorticoids, plasmapheresis, and azathioprine, followed by right hemicolectomy and adjuvant CAPEOX chemotherapy...The temporal relationship and improvement with cancer-directed therapy raise the possibility that malignancy may act as a trigger for clinically overt vasculitis. Recognition of this relationship may help guide appropriate management and avoid unnecessary or prolonged immunosuppression.
    Journal
    |
    MPO (Myeloperoxidase)
    2ms
    Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P2, N=140, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2029 | Trial primary completion date: Jun 2026 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    cyclosporin A microemulsion • methylprednisolone sodium succinate
    2ms
    PROMISE-MG: Disease-Modifying Treatments for Myasthenia Gravis (clinicaltrials.gov)
    P=N/A, N=82, Completed, Duke University | N=167 --> 82
    Enrollment change • HEOR
    2ms
    LAMB-SOT: Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, Sichuan Provincial People's Hospital
    New trial • Real-world evidence
    2ms
    INSTEAD: Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (clinicaltrials.gov)
    P3, N=244, Recruiting, University Hospital, Tours | Trial completion date: Mar 2030 --> Dec 2030 | Trial primary completion date: Mar 2027 --> Dec 2030 | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    2ms
    Disseminated Tuberculosis With Placental Involvement in a Crohn's Disease Patient Treated With Combination Therapy. (PubMed, Gastro Hep Adv)
    We report the case of a 39-year-old pregnant woman with ileal Crohn's disease who developed severe, life-threatening disseminated tuberculosis during treatment with infliximab and azathioprine. The case highlights the possibility of involvement of atypical sites, such as the placenta. In endemic areas, a high index of suspicion is required for uncommon manifestations of the disease.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    2ms
    TEMPO-LT: TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation (clinicaltrials.gov)
    P1/2, N=12, Not yet recruiting, Stanford University
    New P1/2 trial